Review



lightening link streptavidin  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Novus Biologicals lightening link streptavidin
    Fig.4: Decreased capacity of L3P-BLK to facilitate B cell receptor-mediated HLA-DR/peptide presentation to CD4+ T -cells. Tetanus toxoid (TT) protein is complexed with anti-IgG F(ab’)2 fragments in ratio 1:2 or 1:4 for 6 hours at 4C (using <t>streptavidin/</t> biotin conjugation). Paired human B-LCLs expressing common or L3P-BLK variant are loaded (4hrs, 37°C) with 0, 1, or 10 μg anti- IgG-TT complexes. Next, human TT peptide/MHCII-specific CD4+ T-cells are added for co-culture with the B-LCLs (1:1 ratio, O/N, 37°C). B-LCL mediated activation of antigen-specific CD4+ T-cells was measured by analysis of induced CD154 (CD40L) expression. A. CD40L staining in absence of exogenous antigen is set as background levels for both B-LCLs expressing common BLK (upper panel) or L3P-BLK (lower panel). Representative of 3 independent experiments. B. L3P-BLK expressing B-LCL cells (grey) are less able to induce activation of antigen-specific CD4+ T-cells (CD40L high phenotype) compared to common BLK-expressing B-LCL cells (black). Experiments performed on B-LCLs of three independent donors, in at least three independent experiments. Data represented as mean +/- SEM. C. Expression of L3P-BLK does not affect expression of class II MHC molecules (HLA-DR) and co-stimulatory molecules (CD40, CD86, and CD54) in B-LCLs. Data of 3 independent experiments, represented as mean +/- SEM. *P-value <0.05, **P-value <0.01, Two- tailed Wilcoxon-signed rank test.
    Lightening Link Streptavidin, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 14 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lightening+link+streptavidin/Streptavidin+%5BCy3%5D/pm25926555-219-13-19
    Average 92 stars, based on 14 article reviews
    lightening link streptavidin - by Bioz Stars, 2026-10
    92/100 stars

    Images

    1) Product Images from "Dysfunctional BLK in common variable immunodeficiency perturbs B-cell proliferation and ability to elicit antigen-specific CD4+ T-cell help."

    Article Title: Dysfunctional BLK in common variable immunodeficiency perturbs B-cell proliferation and ability to elicit antigen-specific CD4+ T-cell help.

    Journal: Oncotarget

    doi: 10.18632/oncotarget.3577

    Fig.4: Decreased capacity of L3P-BLK to facilitate B cell receptor-mediated HLA-DR/peptide presentation to CD4+ T -cells. Tetanus toxoid (TT) protein is complexed with anti-IgG F(ab’)2 fragments in ratio 1:2 or 1:4 for 6 hours at 4C (using streptavidin/ biotin conjugation). Paired human B-LCLs expressing common or L3P-BLK variant are loaded (4hrs, 37°C) with 0, 1, or 10 μg anti- IgG-TT complexes. Next, human TT peptide/MHCII-specific CD4+ T-cells are added for co-culture with the B-LCLs (1:1 ratio, O/N, 37°C). B-LCL mediated activation of antigen-specific CD4+ T-cells was measured by analysis of induced CD154 (CD40L) expression. A. CD40L staining in absence of exogenous antigen is set as background levels for both B-LCLs expressing common BLK (upper panel) or L3P-BLK (lower panel). Representative of 3 independent experiments. B. L3P-BLK expressing B-LCL cells (grey) are less able to induce activation of antigen-specific CD4+ T-cells (CD40L high phenotype) compared to common BLK-expressing B-LCL cells (black). Experiments performed on B-LCLs of three independent donors, in at least three independent experiments. Data represented as mean +/- SEM. C. Expression of L3P-BLK does not affect expression of class II MHC molecules (HLA-DR) and co-stimulatory molecules (CD40, CD86, and CD54) in B-LCLs. Data of 3 independent experiments, represented as mean +/- SEM. *P-value <0.05, **P-value <0.01, Two- tailed Wilcoxon-signed rank test.
    Figure Legend Snippet: Fig.4: Decreased capacity of L3P-BLK to facilitate B cell receptor-mediated HLA-DR/peptide presentation to CD4+ T -cells. Tetanus toxoid (TT) protein is complexed with anti-IgG F(ab’)2 fragments in ratio 1:2 or 1:4 for 6 hours at 4C (using streptavidin/ biotin conjugation). Paired human B-LCLs expressing common or L3P-BLK variant are loaded (4hrs, 37°C) with 0, 1, or 10 μg anti- IgG-TT complexes. Next, human TT peptide/MHCII-specific CD4+ T-cells are added for co-culture with the B-LCLs (1:1 ratio, O/N, 37°C). B-LCL mediated activation of antigen-specific CD4+ T-cells was measured by analysis of induced CD154 (CD40L) expression. A. CD40L staining in absence of exogenous antigen is set as background levels for both B-LCLs expressing common BLK (upper panel) or L3P-BLK (lower panel). Representative of 3 independent experiments. B. L3P-BLK expressing B-LCL cells (grey) are less able to induce activation of antigen-specific CD4+ T-cells (CD40L high phenotype) compared to common BLK-expressing B-LCL cells (black). Experiments performed on B-LCLs of three independent donors, in at least three independent experiments. Data represented as mean +/- SEM. C. Expression of L3P-BLK does not affect expression of class II MHC molecules (HLA-DR) and co-stimulatory molecules (CD40, CD86, and CD54) in B-LCLs. Data of 3 independent experiments, represented as mean +/- SEM. *P-value <0.05, **P-value <0.01, Two- tailed Wilcoxon-signed rank test.

    Techniques Used: Conjugation Assay, Expressing, Variant Assay, Co-Culture Assay, Activation Assay, Staining, Two Tailed Test

    Related Articles

    Purification:

    Article Title: Dysfunctional BLK in common variable immunodeficiency perturbs B-cell proliferation and ability to elicit antigen-specific CD4+ T-cell help.
    Article Snippet: Goat anti-human IgG and IgM F(ab’)2-fragments (Invitrogen) were conjugated to EZ-link Sulfo-NHS Biotin according to manufactures protocol (Thermo Scientific). .. Purified Tetanus Toxoid (RIVM, the Netherlands) or DQ-BSA (Life Technologies) was conjugated to Lightening-link streptavidin according to manufactures protocol (Novus Biologicals). ..



    Similar Products

    lightening link streptavidin  (Novus Biologicals)
    92
    Novus Biologicals lightening link streptavidin
    Fig.4: Decreased capacity of L3P-BLK to facilitate B cell receptor-mediated HLA-DR/peptide presentation to CD4+ T -cells. Tetanus toxoid (TT) protein is complexed with anti-IgG F(ab’)2 fragments in ratio 1:2 or 1:4 for 6 hours at 4C (using <t>streptavidin/</t> biotin conjugation). Paired human B-LCLs expressing common or L3P-BLK variant are loaded (4hrs, 37°C) with 0, 1, or 10 μg anti- IgG-TT complexes. Next, human TT peptide/MHCII-specific CD4+ T-cells are added for co-culture with the B-LCLs (1:1 ratio, O/N, 37°C). B-LCL mediated activation of antigen-specific CD4+ T-cells was measured by analysis of induced CD154 (CD40L) expression. A. CD40L staining in absence of exogenous antigen is set as background levels for both B-LCLs expressing common BLK (upper panel) or L3P-BLK (lower panel). Representative of 3 independent experiments. B. L3P-BLK expressing B-LCL cells (grey) are less able to induce activation of antigen-specific CD4+ T-cells (CD40L high phenotype) compared to common BLK-expressing B-LCL cells (black). Experiments performed on B-LCLs of three independent donors, in at least three independent experiments. Data represented as mean +/- SEM. C. Expression of L3P-BLK does not affect expression of class II MHC molecules (HLA-DR) and co-stimulatory molecules (CD40, CD86, and CD54) in B-LCLs. Data of 3 independent experiments, represented as mean +/- SEM. *P-value <0.05, **P-value <0.01, Two- tailed Wilcoxon-signed rank test.
    Lightening Link Streptavidin, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/lightening+link+streptavidin/Streptavidin+%5BCy3%5D/pm25926555-219-13-19
    Average 92 stars, based on 1 article reviews
    lightening link streptavidin - by Bioz Stars, 2026-10
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig.4: Decreased capacity of L3P-BLK to facilitate B cell receptor-mediated HLA-DR/peptide presentation to CD4+ T -cells. Tetanus toxoid (TT) protein is complexed with anti-IgG F(ab’)2 fragments in ratio 1:2 or 1:4 for 6 hours at 4C (using streptavidin/ biotin conjugation). Paired human B-LCLs expressing common or L3P-BLK variant are loaded (4hrs, 37°C) with 0, 1, or 10 μg anti- IgG-TT complexes. Next, human TT peptide/MHCII-specific CD4+ T-cells are added for co-culture with the B-LCLs (1:1 ratio, O/N, 37°C). B-LCL mediated activation of antigen-specific CD4+ T-cells was measured by analysis of induced CD154 (CD40L) expression. A. CD40L staining in absence of exogenous antigen is set as background levels for both B-LCLs expressing common BLK (upper panel) or L3P-BLK (lower panel). Representative of 3 independent experiments. B. L3P-BLK expressing B-LCL cells (grey) are less able to induce activation of antigen-specific CD4+ T-cells (CD40L high phenotype) compared to common BLK-expressing B-LCL cells (black). Experiments performed on B-LCLs of three independent donors, in at least three independent experiments. Data represented as mean +/- SEM. C. Expression of L3P-BLK does not affect expression of class II MHC molecules (HLA-DR) and co-stimulatory molecules (CD40, CD86, and CD54) in B-LCLs. Data of 3 independent experiments, represented as mean +/- SEM. *P-value <0.05, **P-value <0.01, Two- tailed Wilcoxon-signed rank test.

    Journal: Oncotarget

    Article Title: Dysfunctional BLK in common variable immunodeficiency perturbs B-cell proliferation and ability to elicit antigen-specific CD4+ T-cell help.

    doi: 10.18632/oncotarget.3577

    Figure Lengend Snippet: Fig.4: Decreased capacity of L3P-BLK to facilitate B cell receptor-mediated HLA-DR/peptide presentation to CD4+ T -cells. Tetanus toxoid (TT) protein is complexed with anti-IgG F(ab’)2 fragments in ratio 1:2 or 1:4 for 6 hours at 4C (using streptavidin/ biotin conjugation). Paired human B-LCLs expressing common or L3P-BLK variant are loaded (4hrs, 37°C) with 0, 1, or 10 μg anti- IgG-TT complexes. Next, human TT peptide/MHCII-specific CD4+ T-cells are added for co-culture with the B-LCLs (1:1 ratio, O/N, 37°C). B-LCL mediated activation of antigen-specific CD4+ T-cells was measured by analysis of induced CD154 (CD40L) expression. A. CD40L staining in absence of exogenous antigen is set as background levels for both B-LCLs expressing common BLK (upper panel) or L3P-BLK (lower panel). Representative of 3 independent experiments. B. L3P-BLK expressing B-LCL cells (grey) are less able to induce activation of antigen-specific CD4+ T-cells (CD40L high phenotype) compared to common BLK-expressing B-LCL cells (black). Experiments performed on B-LCLs of three independent donors, in at least three independent experiments. Data represented as mean +/- SEM. C. Expression of L3P-BLK does not affect expression of class II MHC molecules (HLA-DR) and co-stimulatory molecules (CD40, CD86, and CD54) in B-LCLs. Data of 3 independent experiments, represented as mean +/- SEM. *P-value <0.05, **P-value <0.01, Two- tailed Wilcoxon-signed rank test.

    Article Snippet: Purified Tetanus Toxoid (RIVM, the Netherlands) or DQ-BSA (Life Technologies) was conjugated to Lightening-link streptavidin according to manufactures protocol (Novus Biologicals).

    Techniques: Conjugation Assay, Expressing, Variant Assay, Co-Culture Assay, Activation Assay, Staining, Two Tailed Test